1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Clearmind Medicine reports loss per share of 6.78 USD for quarter ended April 30, 2026
Clearmind Medicine released results for the quarter ended April 30, 2026 and reported a loss per share of 6.78 USD. The figures were announced on June 15, 2026. In the year-ago quarter the loss was -64,000 USD per share. » More on finanzen.net
Financials
| (EUR) | Apr 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -11.85K | 12.05% |
| Net profit | -1.75M | 152.00% |
| EBITDA | -1.33M | 102.10% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.26M |
Number of shares | 1.49M |
52-week high/low | €452.27 - €1.23 |
| Dividends | No |
Beta | -1.25 |
P/E ratio | -0.15 |
PEG ratio | 0.00 |
P/B ratio | 0.05 |
P/S ratio | 0.00 |
Company profile
| Name | CLEARMIND MEDI.INC.O.N. |
| CEO | Adi Zuloff-Shani |
| Employees | 4 |
Discover assets
Shareholders of CLEARMIND MEDI.INC.O.N. also invest in the following assets
